FDA CRL Holds ITM-11 on Manufacturing Issues
FDA issued a Complete Response Letter for ITM’s 177Lu-edotreotide NDA in gastroenteropancreatic neuroendocrine tumors. ITM said the letter cited chemistry, manufacturing and controls and third-party commercial-facility inspection items, without identifying clinical, nonclinical, or safety…
